Wellbutrin vs SSRIs: When Doctors Choose Bupropion First

Two patients present with major depressive disorder. Both have similar PHQ-9 scores. One prescriber reaches for sertraline. The other reaches for bupropion. Both decisions can be correct, but the reasoning behind each is different, and understanding it changes how patients navigate their own treatment.

Bupropion (brand name Wellbutrin) and SSRIs are both considered first-line antidepressants in clinical guidelines. But they work through different mechanisms, produce different side effects, and suit different presentations. The question is not which is better. It is which is better for this patient, with this symptom profile, in this clinical context.

Different Mechanisms, Different Effects

SSRIs (selective serotonin reuptake inhibitors) block the reabsorption of serotonin in synaptic spaces, increasing serotonin availability across mood-regulating circuits. Common SSRIs include sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac), and paroxetine (Paxil). Increased serotonin availability drives the neuroadaptive changes that produce antidepressant effects over four to six weeks.

Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor (NDRI). It works by inhibiting the reuptake of dopamine and norepinephrine, two neurotransmitters more directly associated with motivation, energy, alertness, and reward processing. Bupropion does not significantly affect serotonin. This difference in mechanism is the source of almost every clinical distinction between bupropion and SSRIs.

Because bupropion increases dopamine and norepinephrine activity, it tends to produce effects that feel more activating: improved energy, better concentration, increased motivation. These can be perceived before the full antidepressant effect emerges. Some evidence-based guidelines now support first-line use of bupropion, particularly for presentations where dopaminergic deficits are prominent.

Because bupropion does not meaningfully affect serotonin, it does not produce the side effects most closely tied to serotonergic activity: sexual dysfunction, weight gain, and the emotional blunting some patients describe on SSRIs.

When Bupropion Comes First

Prescribers weigh several specific clinical factors when deciding between bupropion and an SSRI. These are not rigid rules, but they represent the pattern that guides most prescribing decisions.

Fatigue, low energy, and hypersomnia as dominant symptoms. Bupropion is more effective than SSRIs at improving symptoms of hypersomnia and fatigue in patients whose depression manifests primarily as low energy, excessive sleep, and slowed thinking rather than persistent sadness or anxious rumination. When a patient describes their depression as “I can’t get off the couch” more than “I feel hopeless,” bupropion’s dopaminergic mechanism has direct target alignment.

Prior SSRI discontinuation due to sexual dysfunction. Sexual dysfunction is estimated to occur in 50 to 80% of patients taking serotonergic antidepressants, based on questionnaire follow-up, compared to rates comparable to placebo with bupropion. For a patient who stopped a previous SSRI because of decreased libido, delayed orgasm, or erectile dysfunction, bupropion addresses the underlying depression without recreating the side effect that led to discontinuation.

Weight gain as a significant clinical concern. Unlike SSRIs, which are broadly associated with modest weight gain during long-term use, bupropion is not associated with weight gain and may produce modest weight loss in some patients. For patients with metabolic concerns or who cite weight gain as a deterrent to starting or continuing treatment, this distinction matters.

Comorbid ADHD alongside depression. Bupropion is used off-label for ADHD, and its dopaminergic mechanism addresses both the attentional and motivational deficits of ADHD alongside depression. This dual-indication utility makes bupropion a reasonable first choice when ADHD and depression are both present, though this is always evaluated alongside seizure risk and other clinical factors.

Smoking cessation alongside depression treatment. Bupropion is also FDA-approved under the brand name Zyban for smoking cessation. For a patient who smokes and has depression, a prescriber may choose bupropion to address both clinical goals simultaneously.

When SSRIs Come First

Despite bupropion’s advantages in certain presentations, SSRIs remain the standard first-line choice in a number of common clinical scenarios.

Anxiety as the primary or comorbid symptom. Bupropion may worsen anxiety in some patients, particularly at treatment initiation or dose increases. SSRIs are generally preferred for patients whose depression involves significant anxiety, panic features, or OCD symptoms. The serotonergic mechanism addresses anxiety more directly than bupropion does.

First-episode depression without strong symptom subtype indication. When a patient’s symptom profile does not clearly favor one mechanism over the other, SSRIs have the larger evidence base and longer clinical history as the established first-line option. They are the default when the choice is genuinely neutral.

Presence of a seizure risk. Bupropion carries a dose-dependent risk of seizure, with the immediate-release formulation associated with a seizure rate of 4/1000 at higher doses. The sustained-release (SR) and extended-release (XL) formulations substantially reduce this risk, but the seizure consideration remains relevant in patients with a seizure history, eating disorders (which lower seizure threshold), or high alcohol intake.

Bulimia or anorexia nervosa. Bupropion is contraindicated in patients with active or recent bulimia or anorexia nervosa due to a clinically elevated seizure risk in this population. SSRIs are preferred.

The Combination Approach

Bupropion is commonly used alongside SSRIs rather than instead of them. This is the augmentation strategy: adding bupropion when an SSRI has produced partial response, when sexual side effects from the SSRI need to be mitigated, or when energy and motivation remain inadequate despite mood improvement.

A study with nearly 800 participants compared escitalopram to bupropion-SR for depression and found that both were effective as first-line treatments, with no significant difference in overall efficacy. The differentiating factor was not one being more effective, but the specific symptom pattern the patient presented with and the side effects that mattered most to them.

When bupropion is added to an SSRI, the interaction requires attention. Bupropion is a potent inhibitor of the CYP2D6 enzyme, which metabolizes many other medications including some SSRIs. This can raise levels of certain SSRIs when the two are combined. Your prescriber will review your full medication list before adding bupropion to an existing regimen.

Dose and Titration

Bupropion XL (extended-release) is available in 150 mg and 300 mg tablets, taken once daily. Starting dose is typically 150 mg, with a target dose of 300 mg if needed and tolerated. Bupropion SR (sustained-release) is taken twice daily. The XL formulation is preferred for its simpler dosing schedule and more consistent blood levels.

Titration matters. Bupropion should be started at 150 mg and increased gradually rather than jumped directly to higher doses. Rapid titration increases seizure risk and side effects including insomnia, anxiety, and agitation.

Bupropion is typically taken in the morning due to its activating properties. Taking it late in the day can cause insomnia.

Monitoring on Bupropion

Because bupropion has an activating profile, monitoring in the first weeks of treatment should specifically track sleep quality, anxiety levels, and any agitation. These are the side effects most likely to appear early. Most resolve as the dose stabilizes.

“When I choose bupropion over an SSRI, it is almost always because the patient’s symptoms are pointing toward a dopaminergic deficit: low energy, low motivation, sleeping too much, struggling to concentrate,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “But I am also watching the anxiety carefully in the first two weeks. If bupropion is activating anxiety, that changes the picture quickly. Having daily check-in data tells me that is happening before it becomes a reason the patient stops the medication.”

What Members Are Saying

TK

T.K., 38

Major Depressive Disorder

“My first prescriber put me on an SSRI and I gained 15 pounds over a year. I felt better emotionally but hated how I looked. My prescriber at Siggy switched me to bupropion. My energy was better, the weight stabilized, and the sexual side effects I had been dealing with quietly went away. I felt like myself for the first time in years.”

NP

N.P., 44

Depression with Fatigue

“I kept telling doctors I was depressed but my main problem was that I could not function. I could not get out of bed, I could not motivate myself to do anything. Bupropion was the first medication that actually addressed that. The energy came back first. The mood followed.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Bupropion and SSRIs are both valid first-line antidepressants. The choice between them is not a hierarchy but a clinical match between the medication’s mechanism and the patient’s specific symptom pattern, side effect history, and clinical context.

Bupropion belongs first when energy, motivation, and cognitive symptoms dominate, when sexual dysfunction from a prior SSRI was the reason for stopping, or when weight gain is a genuine barrier to treatment. SSRIs belong first when anxiety features are prominent, when the presentation is typical without strong symptom subtype, or when seizure risk factors are present.

The most important thing is not which medication a patient starts on, but whether the monitoring is in place to make informed adjustments as the treatment develops.

Wondering which antidepressant fits your profile? Start your anonymous intake with SiggyMD. A licensed prescriber reviews your full clinical picture before anything is prescribed, with daily check-ins that track how your medication is actually working. Read more about how antidepressant dose adjustments work as your treatment develops.

Sources

• Bupropion. Wellbutrin XL Prescribing Information. FDA. Accessed June 2026.

• National Institute of Mental Health. Mental Health Medications. NIMH. Accessed June 2026.

• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed June 2026.

• Psychiatric Times. Is Bupropion Your No. 1 Antidepressant Choice? Accessed June 2026.

• GoodRx Health. Lexapro vs Wellbutrin for Depression. Accessed June 2026.

• PsychiatryOnline. The American Psychiatric Publishing Textbook of Psychopharmacology. APA. Accessed June 2026.

• Stahl SM. Stahl’s Essential Psychopharmacology. 5th ed. Cambridge. Accessed June 2026.